Compare Keysight Technologies Inc (KEYS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Keysight Technologies Inc trades at $349.84 (market cap $63.03B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Keysight Technologies Inc is far larger — about 8.4× Spyre Therapeutics Inc. Common Stock's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 57 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KEYS | SYRE | |
|---|---|---|
Market Cap | $63.03B | $7.52B |
Volume | 1,168,526 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $387.90 | $108.92 |
52-Week Low | $162.19 | $22.18 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $63.17B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $357.59, down 5.32% over 24 hours, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue for 2025 reached $5.38 billion, with a net income margin of 15.81%. Recent news highlights growth in AI infrastructure and 6G testing solutions.
The outlook remains positive with a consensus price target of $421.29, implying significant upside. Risks include elevated valuation multiples and supply constraints affecting near-term revenue conversion. Institutional sentiment is bullish, with 81% of analysts rating the stock a buy.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
